Disclosure statement
S. Martínez-Fernández has no competing interests to declare that are relevant to the content of this article.
HJ Suh-Oh has received honoraria or support for training activities, has acted as a consultant or has participated in clinical trials from: Abbvie, Celgene, Faes pharma, Isdin, Janssen, Leo-Pharma, Lethipharma, Lilly, Mylan, Novartis, Pfizer, Pierre Fabre, Roche y Sanofi-Genzyme.
A. Batalla has received honoraria or support for training activities, has acted as a consultant or has participated in clinical trials from: Abbvie, Celgene, Faes pharma, Isdin, Janssen, Leo-Pharma, Lethipharma, Lilly, Mylan, Novartis, Pfizer, Pierre Fabre y Sanofi-Genzyme.
C. Couselo-Rodríguez has received honoraria or support for training activities, has acted as a consultant or has participated in clinical trials from: Mylan, Pierre Fabre y Sanofi-Genzyme.
M. Espasandín-Arias has received honoraria or support for training activities, has acted as a consultant or has participated in clinical trials from: Abbvie, Sanofi, Pfizer and LEO Pharma.
Á. Flórez has received honoraria or support for training activities, has acted as a speaker, consultant or has participated in clinical trials from Abbvie, Almirall, Amgen, Celgene, Janssen, Kyowa Kirin, Leo-Pharma, Lilly, Novartis, Pfizer, Roche Farma, Sanofi, Sun Pharma, Takeda and UCB Pharma.
Data availability statement
The data that support the findings of this study are openly available in Pubmed at:
http://doi.org/10.1038/s41572-018-0001-z, reference number 1.
http://doi.org/10.1038/s41573-021-00266-6, reference number 2.
http://doi.org/10.1016/S0140-6736(21)00588-2, reference number 3.
http://doi.org/10.1001/jamadermatol.2022.0029, reference number 4.
http://doi.org/10.1016/j.jaci.2019.11.025, reference number 6.
http://doi.org/10.1007/s40268-022-00396-1, reference number 7.
http://doi.org/10.2340/actadv.v103.5243, reference number 8.